Maximizing the commercial value of personalized therapeutics and companion diagnostics

Nature Biotechnology

Volumn 31, Issue 9, 2013, Pages 803-805

  Zhang, Cynthia H ^a,b   Zhang, Y Philip ^a,b  

^a AGILENT TECHNOLOGIES   (Singapore)

^b Milstein Zhang and Wu   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; COMMERCIAL PHENOMENA; DIAGNOSTIC TEST; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; PATENT; PATIENT CARE; PATIENT INFORMATION; PERSONALIZED MEDICINE; PHARMACEUTICAL CARE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGRAM DEVELOPMENT;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; CLINICAL LABORATORY TECHNIQUES; DRUG DISCOVERY; HUMANS; INDIVIDUALIZED MEDICINE; INTELLECTUAL PROPERTY; PATENTS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 84884163512     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2679     Document Type: Article

References (13)

1. P resident's Council of Advisors on Science and Technology. Priorities for personalized medicine (2008).
2. N aylor, S. &Cole, T. Overview of companion diagnostics in the pharmaceutical industry. Drug Discovery World Spring, 67-79 (2010).
3. FDA. Drug-diagnostic co-development concept paper (US Food and Drug Administration, 2004).
4. FDA. Draft guidance for industry and Food and Drug Administration staff-in vitro companion diagnostic devices (US Food and Drug Administration, 2011).
5. Ziegler, A. et al. Hum. Genet. 131, 1627-1638 (2012).
6. Jørgensen, J. Drug Dev. Res. 73, 390-397 (2012).
7. Jørgensen, J. et al. Oncologist 12, 397-405 (2007).
8. Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 US, 132, S. Ct. 1289, 101 USPQ2d 1961 (2012).
9. 21 USC section 355(b)(1) (2006).
10. Mahn, T.G. Drug Labels: The New Orange Book. Update (The Food & Drug Law Institute) July/August, 8-12 (2006).
11. 21 USC §355(j)(2)(A)(v) (2006).
12. 21 CFR §314.94(a)(8)(iv) (2007).
13. 21 CFR §314.127(a)(7) (2007).